BioNTech
NEWS
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
The U.S. appears to be beating back COVID-19 but it’s still raging in many parts of the world, and studies and trials are still ongoing. Here’s a look at some of today’s top COVID-19 stories.
The data may show the need for one, but vaccine and immunologists are pushing back against Pfizer and BioNTech’s contention that one is necessary now.
HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”
The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
It’s a busy news day for COVID-19-related stories. Read on for more.
Here’s a look at some of the top COVID-19-related stories for today.
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
JOBS
IN THE PRESS